Description: Zenith Capital Corp., a biotechnology investment company, focuses on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with unmet medical needs. Its lead compound ZEN-3694 which is in phase 1b/2a that is in clinical development for metastatic castration resistant prostate cancer and triple negative breast cancer. The company was incorporated in 2013 and is based in Calgary, Canada.
Home Page: www.zenithepigenetics.com
4820 Richard Road SW
Calgary,
AB
T3E 6L1
Canada
Phone:
Officers
| Name | Title |
|---|---|
| Mr. Donald J. McCaffrey | Chairman, Pres & CEO |
| Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV | CFO & Sec. |
| Dr. Sanjay Lakhotia M.B.A., Ph.D. | Chief Bus. Officer |
| Dr. Henrik Claus Hansen Ph.D. | Sr. VP of Operations |
| Dr. Huan Zhu | Chief Medical Officer |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | April |
| Full Time Employees: | 0 |